Search results for "co-morbiditie"

showing 7 items of 7 documents

Finnish version of the Tampa Scale of Kinesiophobia: Reference values in the Finnish general population and associations with leisure-time physical a…

2014

[Abstract.] Objectives: To create reference values for the general Finnish population using the Tampa Scale of Kinesiophobia (TSK-FIN), to study gender differences in the TSK-FIN, to assess the internal consistency of the TSK-FIN, to estimate the prevalence of high levels of kinesiophobia in Finnish men and women, and to examine the association between kinesio-phobia and leisure-time physical activity and the impact of co-morbidities on kinesiophobia. Methods: The study population comprised 455 men and 579 women. Participants completed a self-administered questionnaire about their socio-demographic factors, leisure-time physical activity, co-morbidities and kinesiophobia. Results: The mean …

AdultMalemedicine.medical_specialtyPsychometricsPsychometricsPopulationPhysical activityphysical activityPhysical Therapy Sports Therapy and RehabilitationMotor ActivityLeisure ActivitiesCronbach's alphaReference ValuesSurveys and QuestionnairesPrevalencemedicineviitearvotHumansMusculoskeletal DiseaseseducationFinlandPain MeasurementSex Characteristicseducation.field_of_studyRehabilitationFearGeneral MedicineMiddle Agedco-morbiditiesPhobic DisordersReference valuesScale (social sciences)Physical therapyPopulation studyFemalePsychologyLow Back Painpain-related fearSex characteristics
researchProduct

EuropeaN Energy balance Research to prevent excessive weight Gain among Youth (ENERGY) project: Design and methodology of the ENERGY cross-sectional …

2011

Abstract Background Obesity treatment is by large ineffective long term, and more emphasis on the prevention of excessive weight gain in childhood and adolescence is warranted. To inform energy balance related behaviour (EBRB) change interventions, insight in the potential personal, family and school environmental correlates of these behaviours is needed. Studies on such multilevel correlates of EBRB among schoolchildren in Europe are lacking. The ENERGY survey aims to (1) provide up-to-date prevalence rates of measured overweight, obesity, self-reported engagement in EBRBs, and objective accelerometer-based assessment of physical activity and sedentary behaviour and blood-sample biomarkers…

Gerontologymedicine.medical_specialtyCross-sectional studyPsychological interventionPEDIATRIC OBESITY030209 endocrinology & metabolismCHILDRENHealth PromotionOverweightWeight GainChildhood obesity03 medical and health sciencesStudy Protocol0302 clinical medicineSDG 3 - Good Health and Well-beingMedicine and Health SciencesCO-MORBIDITIESMedicineHumans030212 general & internal medicineObesityChildExerciseSedentary lifestyleSchoolsAnthropometrybusiness.industryFRUITPublic healthlcsh:Public aspects of medicinePublic Health Environmental and Occupational Healthlcsh:RA1-1270ASSOCIATIONAnthropometrymedicine.diseaseEuropePHYSICAL-ACTIVITYCross-Sectional Studies/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingESTIMATED BURDENBiostatisticsmedicine.symptomCHILDHOOD OBESITYSedentary BehaviorbusinessEnergy IntakeRisk Reduction BehaviorBMC Public Health
researchProduct

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

2023

Abstract Background We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admiss…

MaleEpidemiologyMESH: HospitalizationMESH: Proportional Hazards ModelsMESH: Risk FactorsRisk FactorsMESH: Childcohort studyMESH: COVID-19HumansMESH: SARS-CoV-2ChildProportional Hazards ModelsMESH: HumansMESH: Middle AgedSARS-CoV-2COVID-19risk of deathGeneral MedicineMiddle AgedCOVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatmentsMESH: MaleHospitalizationIntensive Care Unitsco-morbiditiestreatmentssymptomsMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCOVID-19/therapy
researchProduct

Prevalence of Co-morbidities and severity of COPD

2014

Abstract We aimed at exploring whether the prevalence of co-morbidities of chronic obstructive pulmonary disease (COPD) increases with COPD severity. Analysis of medical records of outpatients with established diagnosis of COPD was retrospectively performed. The lower limit of normality (LLN) for FEV1/FVC was applied to establish the occurrence of airway obstruction in the elderly population. The prevalence of co-morbidities was calculated, and the proportion of patients with each co-morbidity along with GOLD stages was analysed by chi-square for trend. A total of 326 (M/F: 256/70) consecutive outpatients with COPD (stage GOLD I to IV), aging 71.8 ± 9.2 years, were included in the analysis.…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtysystemic effectsprevalenceComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexCoronary artery diseasePulmonary Disease Chronic ObstructiveFEV1/FVC ratioco-morbiditieInternal medicineDiabetes mellitusEpidemiologymedicineHumansCOPDAgedRetrospective StudiesAged 80 and overCOPDbusiness.industryMiddle AgedAirway obstructionmedicine.diseaserespiratory tract diseasesHeart failurePhysical therapyFemaleepidemiologyUnderweightmedicine.symptombusiness
researchProduct

Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort.

2021

AbstractManagement for HCV has undergone a notable change using direct-acting antiviral drugs (DAAs), which are safe and effective even in elderly. Here, we define impact of comorbidities, concomitant medication and drug–drug interactions in elder patients with HCV related disease before starting DAAs regimen. We analyzed data of 814 patients prospectively enrolled at our Unit within the web based model HCV Sicily Network. Out of 814, 590 were treated with DAAs and 414 of them were older than 65 years. We divided those 414 in two groups, one including 215 patients, aged between 65 and 74 years, and another with 199 patients, aged of 75 years and over. Charlson Comorbidity Index (CCI) was as…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaComorbidityHepacivirusDDI int eractionAntiviral AgentsCo-morbiditieDe-prescribing03 medical and health sciencesLiver diseaseElderly0302 clinical medicineQuality of lifeInternal medicineDiabetes mellitusInternal MedicinemedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyDepression (differential diagnoses)Agedbusiness.industryCharlson IndexHepatitis C Chronicmedicine.diseaseRegimenHCVEmergency MedicineQuality of Life030211 gastroenterology & hepatologyFemalebusinessDyslipidemiaKidney diseaseInternal and emergency medicine
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Co-morbidities in patients with hip osteoarthritis and treated with ecoguided infiltrations of Hyaluronic acid: study of the effectiveness of the tre…

2014

Settore MED/33 - Malattie Apparato Locomotoreosteoarthritis co-morbidities ecoguided infiltrations hyaluronic acid
researchProduct